Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

OptimizeRx (OPRX) EBITDA Margin: 2010-2025

Historic EBITDA Margin for OptimizeRx (OPRX) over the last 16 years, with Q3 2025 value amounting to 7.86%.

  • OptimizeRx's EBITDA Margin rose 480400.0% to 7.86% in Q3 2025 from the same period last year, while for Sep 2025 it was 6.17%, marking a year-over-year increase of 382000.0%. This contributed to the annual value of 14.76% for FY2024, which is 220200.0% up from last year.
  • According to the latest figures from Q3 2025, OptimizeRx's EBITDA Margin is 7.86%, which was up 480400.0% from 10.92% recorded in Q2 2025.
  • OptimizeRx's EBITDA Margin's 5-year high stood at 11.25% during Q4 2024, with a 5-year trough of 54.32% in Q1 2023.
  • Over the past 5 years, OptimizeRx's median EBITDA Margin value was 19.93% (recorded in 2024), while the average stood at 15.76%.
  • As far as peak fluctuations go, OptimizeRx's EBITDA Margin plummeted by -340400bps in 2023, and later skyrocketed by 496800bps in 2024.
  • Over the past 5 years, OptimizeRx's EBITDA Margin (Quarter) stood at 3.06% in 2021, then plummeted by -244bps to 4.4% in 2022, then plummeted by -774bps to 38.43% in 2023, then soared by 129bps to 11.25% in 2024, then plummeted by -30bps to 7.86% in 2025.
  • Its EBITDA Margin was 7.86% in Q3 2025, compared to 10.92% in Q2 2025 and 9.64% in Q1 2025.